(NasdaqGM:ALLR), TARPON SPRINGS, Fla., August 26, 2025 — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib–a differentiated, dual PARP and WNT pathway inhibitor–today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to stenoparib, its investigational treatment for patients […]

(SWX:HODL),(SWX:ABTC),(SWX:ABCH),(SWX:ABBA),(SWX:KEYS),(SWX:ABNB),(SWX:AETH),(SWX:AXRP),(SWX:AXTZ),(Paris:ABTC),(Paris:AETH),(Paris:SBTC),(Euronext Amsterdam:2BTC),(Euronext Amsterdam:BTCS),(Euronext Amsterdam:2ETH),(SWX:ADOT SE),(SWX:AADA SE),(SWX:AXLM SE),(SWX:SBTC SE),(LSE:ETHC LN),(LSE:CETU LN),(LSE:CBTC LN),(LSE:CBTU LN),(LSE:AETH LN),(LSE:ETHU LN),(LSE:BTCU LN),(LSE:ABTC LN), NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) — 21Shares US LLC today announced the renaming of the 21Shares Ethereum Core ETF (CETH) or “the Fund” to the 21Shares Ethereum ETF (TETH), effective August 28, 2025. The changes do not

VIENNA and LAUSANNE, Switzerland, Aug. 26, 2025 (GLOBE NEWSWIRE) — Proxygen, a global leader in the discovery and development of molecular glue degraders, today announced a strategic research collaboration with EPFL (the Swiss Federal Institute of Technology in Lausanne). The partnership combines Proxygen's validated glue degrader discovery platform with the pioneering work of Professor Bruno

(NASDAQ:TASK), SAN DIEGO, Aug. 26, 2025 (GLOBE NEWSWIRE) — Shareholder rights law firm Johnson Fistel, PLLP is investigating whether the board of directors of TaskUs, Inc. (NASDAQ: TASK) breached their fiduciary duties in connection with the proposed sale of the company to Blackstone, TaskUs Co-Founder and CEO Bryce Maddock, and Co-Founder and President Jaspar Weir

Cambridge, MA, Aug. 26, 2025 (GLOBE NEWSWIRE) — CAMBRIDGE, Mass, August 26, 2025 – Organizations face enormous pressure to adapt to shifting customer expectations, emerging technologies, and new competitive threats. But in a recent research report from Deloitte, employees surveyed across organizational hierarchies said they spent roughly half their day (41%) on work that created

DETROIT, Aug. 26, 2025 (GLOBE NEWSWIRE) — IAV Group (“IAV”), a global leader in automotive engineering specializing in tech-driven, software-defined solutions, today announced it has joined SDVerse âˆ' the automotive industry's first B2B marketplace dedicated to software. As a trusted partner to leading OEMs, IAV supports the development of next-generation mobility solutions across the vehicle

(NASDAQ:FRSX),(TASE:FRSX.TA), The project will evaluate the integration of Eye-Net's advanced safety technology into Continental's vehicle platforms Ness Ziona, Israel, Aug. 26, 2025 (GLOBE NEWSWIRE) — Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in 3D perception systems, announced that its wholly-owned subsidiary, Eye-Net Mobile Ltd. (“Eye-Net”), has signed an

(NASDAQ:AIFF), – Unlocks exciting new AI-driven brain biomarker discovery and advancement capabilities – – Substantial processing speed gains while maintaining high signal quality standards – – Comes just months after Firefly announced its acceptance into the NVIDIA Connect Program – KENMORE, Wash. and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) — Firefly Neuroscience, Inc. (“Firefly”

(TSX:BCT),(NASDAQ:BCTX),(NASDAQ:BCTXW),(NASDAQ:BCTXZ), Data from BriaCell and the US National Cancer Institute (NCI) support the cancer cell killing potential of BriaCell's Bria-OTS+ platform Bria-OTS+, a novel personalized, off-the-shelf, semi-allogeneic cellular immunotherapy may address urgent unmet medical needs for patients with cancer This study was conducted in collaboration with the NCI PHILADELPHIA and VANCOUVER, British Columbia, Aug. 26,

(NASDAQ:CURX), Jericho, New York, Aug. 26, 2025 (GLOBE NEWSWIRE) — Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced the pricing of its initial public offering (the “Offering”) of 3,750,000 shares of common stock at a public offering